Literature DB >> 15598005

Botulinum neurotoxin serotype A: a clinical update on non-cosmetic uses.

P David Charles1.   

Abstract

PURPOSE: Clinical experience with botulinum toxin type A for non-cosmetic uses that are approved by the Food and Drug Administration (FDA) and various other non-cosmetic uses that are not approved by FDA, including some applications that are widely known and others that currently are emerging, is discussed.
SUMMARY: FDA-approved indications for botulinum toxin type A (Botox) include the temporary treatment of cervical dystonia (a neuromuscular disorder involving the head and neck), the oculomotor disorders strabismus (improperly aligned eyes) and blepharospasm (involuntary contraction of the eye muscles), and severe primary axillary hyperhidrosis (excessive sweating). Other uses of botulinum toxin type A that are widely known but not approved by FDA include spastic disorders associated with injury or disease of the central nervous system including trauma, stroke, multiple sclerosis, or cerebral palsy and focal dystonias affecting the limbs, face, jaw, or vocal cords. Treatment and prevention of chronic headache and chronic musculoskeletal pain are emerging uses for botulinum toxin type A.
CONCLUSION: Many of the conditions for which botulinum toxin type A has been explored are common and difficult to treat. Temporary improvement in symptoms is associated with botulinum toxin type A injection, and repeat treatment often is required. The drug is well tolerated and has a wide margin of safety.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15598005     DOI: 10.1093/ajhp/61.suppl_6.S11

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  11 in total

Review 1.  The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain: a systematic review and meta analysis.

Authors:  Tony Zhang; Aleem Adatia; Wasifa Zarin; Misha Moitri; Abi Vijenthira; Rong Chu; Lehana Thabane; Walter Kean
Journal:  Inflammopharmacology       Date:  2010-11-13       Impact factor: 4.473

Review 2.  The Molecular Basis of Toxins' Interactions with Intracellular Signaling via Discrete Portals.

Authors:  Adi Lahiani; Ephraim Yavin; Philip Lazarovici
Journal:  Toxins (Basel)       Date:  2017-03-16       Impact factor: 4.546

3.  Synthesis and biological evaluation of botulinum neurotoxin a protease inhibitors.

Authors:  Bing Li; Ramdas Pai; Steven C Cardinale; Michelle M Butler; Norton P Peet; Donald T Moir; Sina Bavari; Terry L Bowlin
Journal:  J Med Chem       Date:  2010-03-11       Impact factor: 7.446

4.  [Effect of botulinum toxin type B on residual limb sweating and pain. Is there a chance for indirect phantom pain reduction by improved prosthesis use?].

Authors:  K-U Kern; M Kohl; U Seifert; T Schlereth
Journal:  Schmerz       Date:  2012-04       Impact factor: 1.107

5.  Stem cell derived phenotypic human neuromuscular junction model for dose response evaluation of therapeutics.

Authors:  Navaneetha Santhanam; Lee Kumanchik; Xiufang Guo; Frank Sommerhage; Yunqing Cai; Max Jackson; Candace Martin; George Saad; Christopher W McAleer; Ying Wang; Andrea Lavado; Christopher J Long; James J Hickman
Journal:  Biomaterials       Date:  2018-02-27       Impact factor: 12.479

6.  Novel Benzimidazole Inhibitors of Botulinum Neurotoxin/A Display Enzyme and Cell-Based Potency.

Authors:  Steven C Cardinale; Michelle M Butler; Gordon Ruthel; Jonathan E Nuss; Laura M Wanner; Bing Li; Ramdas Pai; Norton P Peet; Sina Bavari; Terry L Bowlin
Journal:  Botulinum J       Date:  2011

7.  Safety and efficacy of botox injection in alleviating post-operative pain and improving quality of life in lower extremity limb lengthening and deformity correction.

Authors:  Reggie C Hamdy; Kathleen Montpetit; Joanne Ruck-Gibis; Kelly Thorstad; Ellen Raney; Michael Aiona; Robert Platt; Allen Finley; William Mackenzie; James McCarthy; Unni Narayanan
Journal:  Trials       Date:  2007-09-28       Impact factor: 2.279

Review 8.  Novel Treatment of Chronic Bladder Pain Syndrome and Other Pelvic Pain Disorders by OnabotulinumtoxinA Injection.

Authors:  Jia-Fong Jhang; Hann-Chorng Kuo
Journal:  Toxins (Basel)       Date:  2015-06-18       Impact factor: 4.546

Review 9.  Botulinum Toxin Application in Facial Esthetics and Recent Treatment Indications (2013-2018).

Authors:  Vivekanand Kattimani; Rahul Vinay Chandra Tiwari; Khalid Gufran; Bharti Wasan; P H Shilpa; Anas Abdul Khader
Journal:  J Int Soc Prev Community Dent       Date:  2019-04-12

Review 10.  Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders.

Authors:  Yu-Hua Lin; Bing-Juin Chiang; Chun-Hou Liao
Journal:  Toxins (Basel)       Date:  2020-02-18       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.